Keros Therapeutics, Inc.
KROS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $0 | $1 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -21.5% | -91.4% | 6,844.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 97.2% | 98% | 100% | 89.1% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -58.3% | -179.2% | 72.1% | -958% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -51% | -169% | 70.3% | -1,513% |
| EPS Diluted | -0.18 | -0.76 | 3.62 | -1.14 |
| % Growth | 76.3% | -121% | 417.5% | – |
| Operating Cash Flow | $0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | -$0 |